Altered Expression of Cell Cycle Regulators in Myxofibrosarcoma, with Special Emphasis on Their Prognostic Implications

Human Pathology

Volumn 34, Issue 10, 2003, Pages 1035-1042

  Oda, Yoshinao ^a   Takahira, Tomonari ^a   Kawaguchi, Kenichi ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Matsuda, Shuichi ^a   Tanaka, Kazuhiro ^a   Kinukawa, Naoko ^a   Iwamoto, Yukihide ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cell cycle regulator; Immunohistochemistry; Myxofibrosarcoma; Myxoid malignant fibrous histiocytoma

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN D1; CYCLIN E; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; FEMALE; FIBROMYXOSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; PROGNOSIS; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TUMOR VOLUME;

EID: 0142139256     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/S0046-8177(03)00404-0     Document Type: Article

References (32)

1. Fletcher CDM: Pleomorphic malignant fibrous histiocytoma: Fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 16:213-228, 1992
2. Hollowood K, Fletcher CDM: Malignant fibrous histiocytoma: Morphologic pattern or pathologic entity? Semin Diag Pathol 12:210-220, 1995
3. Fletcher CDM, Gustafson P, Rydholm A, et al: Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: Prognostic relevance of subclassification. J Clin Oncol 19:3045-3050, 2001
4. Angervall L, Kindblom LG, Merck C: Myxofibrosarcoma: A study of 30 cases. Acta Pathol Microbiol Scand (A) 85:127-140, 1977
5. Mentzel T, Calonje E, Wadden C, et al: Myxofibrosarcoma: Clinicopathologic analysis of 75 cases with emphasis on low-grade variant. Am J Surg Pathol 20:391-405, 1996
6. Mentzel T, van den Berg E, Molenaar WM: Myxofibrosarcoma, in Fletcher CDM, Unni KK, Mertens F (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 102-103
7. Cordon-Cardo C, Latres E, Drobnjak M, et al: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794-799, 1994
8. Würl P, Meye A, Schmidt H, et al: High prognostic significance of Mdm2/p53 co-overexpression on soft tissue sarcomas of the extremities. Oncogene 16:1183-1185, 1998
9. Kawai A, Noguchi M, Beppu Y, et al: Nuclear immunoreaction of p53 protein in soft tissue sarcomas: A possible prognostic factor. Cancer 73:2499-2505, 1994
10. Orlow I, Drobnajk M, Zhang ZF, et al: Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival. J Natl Cancer Inst 91:73-79, 1999
11. Sherr CJ: Mammalian G1 cyclins. Cell 73:1059-1065, 1993
12. Xiong J, Hannon GJ, Zhang H: p21 is a universal inhibitor of cell kinases. Nature 366:701-704, 1993
13. Chellappan SP, Giordano A, Fisher PB: Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development, in Vogt PK, Reed SI (eds): Cyclin-Dependent Kinase (CDK) Inhibitors. Berlin, Springer-Verlag, 1998, pp 53-103
14. Dei Tos AP, Piccinin S, Doglioni C, et al: Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol 151:1531-1539, 1997
15. Antonescu CR, Leung DH, Dudas M, et al: Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. Am J Pathol 156:977-983, 2000
16. Noguchi T, Dobashi Y, Minehara H, et al: Involvement of cyclins in cell proliferation and their clinical implications in soft tissue smooth muscle tumors. Am J Pathol 156:2135-2147, 2000
17. Kawauchi S, Goto Y, Liu X-P, et al: Low expression of p27Kip1, a cyclin-dependent kinase inhibitor, is a marker of poor prognosis in synovial sarcoma. Cancer 91:1005-1012, 2001
18. Weiss SW, Sobin L (eds): World Health Organization Histological Typing of Soft Tissue Tumours, 2nd ed. Berlin, Springer-Verlag, 1994
19. Weiss SW, Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors, 4th ed. St. Louis, MO, Mosby, 2001, pp 422-435
20. Coindre J, Bui NB, Bonichon F, et al: Histopathologic grading in spindle cell soft tissue sarcomas. Cancer 61:2305-2309, 1988
21. Fleming ID, Cooper JS, Henson DE, (eds): Soft tissue sarcoma. in American Joint Committee on Cancer. Cancer Staging Manual (5th ed). Philadelphia, PA, Lippincott-Raven, 1998, pp 149-156
22. Kratzke RA, Greatens TM, Rubins JB, et al: Rb and p16 INK4a expression in resected non-small cell lung tumors. Cancer Res 56:3415-3420, 1996
23. Guillou L, Coindre JM, Bonichon F, et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading system in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350-362, 1997
24. Weiss SW, Enzinger FM: Myxoid variant of malignant fibrous histiocytoma. Cancer 39:1672-1685, 1977
25. Salo JC, Lewis JJ, Woodruff JM, et al: Malignant fibrous histiocytoma of the extremity. Cancer 85:1765-1772, 1999
26. Bartkova J, Lukas J, Strauss M, et al: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778, 1995
27. Birindelli S, Perrone F, Oggionni M, et al: Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81:833-844, 2001
28. Lopez-Guerrero JA, Pellin A, Noguera R, et al: Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81:803-814, 2001
29. kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323, 1999
30. Huang LW, Chou YY, Chao SL, et al: p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: Overexpression of p53 predicts poor prognosis. Gynecol Oncol 83:348-354, 2001
31. Noda H, Maehara Y, Irie K, et al: Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAF1/CIP1 in early gastric carcinoma. Cancer 92:1828-1835, 2001
32. Pasz-Walczak G, Kordek R, Faflik M: p21(WAF1) expression in colorectal cancer: Correlation with p53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathol Res Pract 197: 683-689, 2001